Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2007-11-27
2007-11-27
Berch, Mark L. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C546S022000, C546S223000
Reexamination Certificate
active
10154699
ABSTRACT:
A method for resolving enantiomers of a compound containing the structure of the forula:wherein R4or R5may contan one or more asymmetric centers, by mixing a racemic mixture of enantiomers of a compound, containing the structure of said formula; in a solvent, with a resolving compound having a defined sterospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers in sterospecific form and collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystallizing the enantiomer contained in said solution.
REFERENCES:
patent: 4814477 (1989-03-01), Wijnberg et al.
patent: 5389509 (1995-02-01), Maskasky
patent: 5686457 (1997-11-01), Traxler et al.
patent: 6080747 (2000-06-01), Uckun et al.
patent: 6136595 (2000-10-01), Ihle et al.
patent: 6180636 (2001-01-01), Traxler et al.
patent: 6187552 (2001-02-01), Roberds et al.
patent: 6610847 (2003-08-01), Blumenkopf et al.
patent: 6635762 (2003-10-01), Blumenkopf et al.
patent: 6696567 (2004-02-01), Blumenkopf et al.
patent: 6965027 (2005-11-01), Flanagan et al.
patent: 2001/0053782 (2001-12-01), Blumenkopf et al.
patent: 2002/0019526 (2002-02-01), Blumenkopf et al.
patent: 2002/0068746 (2002-06-01), Blumenkopf et al.
patent: 0795556 (1997-09-01), None
patent: 0682027 (1997-10-01), None
patent: WO 9519774 (1995-07-01), None
patent: WO 9713771 (1995-10-01), None
patent: WO 9802437 (1996-07-01), None
patent: WO 9802438 (1996-07-01), None
patent: WO 9640142 (1996-12-01), None
patent: WO 9702262 (1997-01-01), None
patent: WO 9702266 (1997-01-01), None
patent: WO 9718212 (1997-05-01), None
patent: WO 9727199 (1997-07-01), None
patent: WO 9728161 (1997-08-01), None
patent: WO 9732879 (1997-09-01), None
patent: WO 9749706 (1997-12-01), None
patent: WO 9807726 (1998-02-01), None
patent: WO 9823613 (1998-06-01), None
patent: WO 9833798 (1998-08-01), None
patent: WO 9951599 (1999-10-01), None
patent: WO 9961428 (1999-12-01), None
patent: WO 9965908 (1999-12-01), None
patent: WO 9965909 (1999-12-01), None
patent: WO 0000202 (2000-01-01), None
patent: WO 0010981 (2000-03-01), None
patent: WO 0142246 (2001-06-01), None
patent: WO 0200661 (2002-01-01), None
patent: WO 0348162 (2003-06-01), None
“Advanced Organic Chemistry: Reactions, Mechanisms and Structure” 4thed., (Jerry March, Wiley and Sons, 1992) p. 641-644.
J. J. O'Shea, et al.,Phosphorylation and activation of the Jak-3 Janus Kinase in response to Interleukin-2, Nature, 370, 151 (1994).
S. M. Russell, et al.,Interaction of IL-2Rβand γc Chains with Jak1 and Jak3: Implications for XSCID and XCID, Science, 266, 1042 (1994).
J. N. Ihle,The Janus Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling, Adv. Immunology, 60, 1, (1995).
J. N. Ihle,The Janus Protein Tyrosine Kinases in hematopoietic cytokine signaling, Semin. Immunology, 7, 247, (1995).
T. Musso, et al.,Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukings 2, 4, and 7, J. Exp. Med., 181, 1425 (1995).
R. A. Kirken, et al.,Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 Recruitment by a COOH-terminal region of the IL-2-receptor β-chain, Cytokine, 7 689, (1995).
M. G. Malabarba, et al.,Activation of JAK3, but not JAK1, is Critical to Interleukin-4 (IL4) Stimulated Proliferation and Requires a Membrane-proximal Region of IL4 Receptor α*, J. Biol. Chem., 270, 9630, (1995).
J. H. Hanke, B. A. Pollok, and P. S. Changelian,Role of tyrosine kinases in lymphocyte activation: Targets for drug intervention. Inflamm. Res., 44, 357, (1995).
E. E. Eynon, et al.,Disruption of Cytokine Signaling in Lymphoid Development: Unique Contributions of the Common Cytokine Gamma Chain and the JAK3 Kinase, J. Interferon Cytokine Res., 16, 677, (1996).
S. A. Oakes, et al.,Signaling via IL-2 and IL-4 in JAK#-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways, Immunity, 5, 605 (1996).
L. D. Norangelo, et al,Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase, Prog. Immunodeficiency, 6, 61, (1996).
D. C. Thomis, et al.,Peripheral Expression of JAK3 is Required to Maintain T Lymphocyte Function, J. Exp. Med., 185, 197, (1997).
B. H. Nelson, et al.,Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor γc chain for Janus kinase activation leading to T cell proliferation, Proc. Natl. Acad. Sci. USA, 94, 1878, (1997).
A. M. Baird, et al.,T Cell development and activation in Jak3-deficient mice, J. Leukocyte Biol., 63, 669, (1998).
K. D. Liu, et al.,JAK/STAT signaling by cytokine receptors, Curr. Opin. Immunol., 1998, 10:271-278.
W. J. Leonard and J. J. O'Shea,JAKS and STATS: Biological Implications, Annu. Rev. Immunol., 16, 293, (1998).
F. Candotti, et al.,Severe combined immune deficiencies due to defects in the common γ chain-JAK3 signaling pathway, Springer Semin. Immuopathol., 19, 401, (1998).
R. Malaviya, et al.,Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis, J. Biol. Chem., 274, 27028 (1999).
D. C. Thomis, et al.,The Jak Family Tyrosine Kinase Jak3 is Required for IL-2 Synthesis by Naive/Resting CD4+ T Cells, J. Immunol., 163, 5411 (1999).
E. Chen, et al.,Advances in Cytokine Signaling: The Role of Jaks and STATs, Transplantation Proc., 31, 1482, (1999).
R. Moriggi, et al.,Stat5 Activation is Uniquely Associated with Cytokine Signaling in Peripheral T Cells, Immunity, 11, 225 (1995).
L. H. Wang, et al.,JAK3, STAT, and MAPK Signaling Pathways as Novel Molecular Targets for the Tyrphostin AG-490 Regulation of IL-2-Mediated T Cell Response, J. Immunol., 162, 3897, (1999).
E. A. Sudbeck, et al.,Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents, Clin. Cancer Res., 5, 1569, (1999).
F. M. Uckun, et al.,In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [40(4′-Hydroxyphenyl)-Amino-6, 7-Dimethosyquinazoline], Clin. Cancer Research, 5, 2954, (1999).
E. A. Sudbeck and F. M. Uckun,Recent Advances in JAK3 kinase inhibitors, IDrugs, 2, 1026, (1999).
R. Malaviya, et al.,Genetic and Biochemical Evidence for a Critical Role of Janus Kinase(JAK)-3 in Mast Cell-Mediated Type I Hypersenstivity Reactions, Biochem. Biophys., Res. Commun., 257, 807, (1999).
V. N. Trieu, et al.,A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis, Biochem. Biophys. Res. Commun., 267, 22, (2000).
X. C. Li, et. al.,Blocking the Common γ-Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-Term Islet Allograft Survival, J. Immunol., 164, 1193 (2000).
R. Malaviya, et al.,Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′, 5′-Dibromo-4 ′hydroxphenyl)amino-6, 7-dimethoxyquinazoline(WHI-P97),J. Pharmacol. Exp. Ther., 295, 912 (2000).
Traxler, P. M., et al.,Protein tyrosine kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents. (1997), 7 (6): 571-588.
Traxler, P. M., et al.,4-(phenylamino)pyrrolopyrimidine: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase, J. Med. Chem., (1996), 39, 2285-2292.
Jacques, Jean,Enantiomers, racemates, and resolutions, J. Riley & Sons, Inc. XP002208813, (1981) 251-273.
Bayley, C.R., et al.Resolution of Racemates by Diastereomeric Salt Formation, J. Riley & Sones, England, XP002208814, (1992)69-77, inChirality in industry: the commercial manufacture and applications of optically active compounds.
Patent Abstracts of Japan, vol. 1996, No. 4, Apr. 30, 1996 and JP 07330732 A (Kyorin Pharmaceut Co., LTD) Dec. 19, 1995.
Flanagan Mark E.
Munchhof Michael J.
Benson Gregg C.
Berch Mark L.
Lee Christine S.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Chiral salt resolution does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chiral salt resolution, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chiral salt resolution will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3878761